Innate Pharma (IPHA) Reports FY22, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
March 23, 2023 2:00 AM EDTSanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with 25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash position of 136.6 million2 as of December 31, 2022 (not including the 25 million payment from Sanofi), anticipated cash runway into mid... More
